Mortality after diagnosis of psychiatric disorders and co-occurring substance use disorders among HIV-infected patients.

We examined the associations between psychiatric diagnoses, substance use disorders, health services, and mortality among 9751 HIV-infected patients (≥14 years old) in a large, private medical care program, in a retrospective cohort design over a 12-year period. All study data were extracted from computerized clinical and administrative databases. Results showed that 25.4% (n = 2472) of the 9751 study subjects had received a psychiatric diagnosis (81.1% had major depression, 17.1% had panic disorder, 14.2% had bipolar disorder, and 8.1% had anorexia/bulimia); and 25.5% (n = 2489) had been diagnosed with substance use disorder; 1180 (12.1%) patients had received both psychiatric and substance diagnoses. In comparison to patients with neither a psychiatric diagnosis nor a SU diagnosis, the highest risk of death was found among patients with dual psychiatric and substance use diagnoses who had no psychiatric treatment visits and no substance treatment (relative hazards [RH] = 4.17, 95% confidence interval [CI] = 2.35 to 7.40). Among dually diagnosed patients, receiving psychiatric and/or substance use disorder treatment somewhat reduced the risk of death compared to patients with neither diagnosis. The lowest risks of death were observed among patients with a single diagnosis who had received corresponding treatment. Our study findings suggest that screening for psychiatric and substance problems at the initiation and during the course of HIV/AIDS treatment and providing psychiatric and substance use disorder treatment may extend life for these vulnerable patients.

[1]  Nancy Gordon,et al.  Ethnic Disparities in Accessing Treatment for Depression and Substance Use Disorders in an Integrated Health Plan , 2010, International journal of psychiatry in medicine.

[2]  W. Mkanta,et al.  Race, outpatient mental health service use, and survival after an AIDS diagnosis in the highly active antiretroviral therapy era. , 2010, AIDS patient care and STDs.

[3]  D. Spiegelman,et al.  Incident Depression Symptoms Are Associated With Poorer HAART Adherence: A Longitudinal Analysis From the Nutrition for Healthy Living Study , 2010, Journal of acquired immune deficiency syndromes.

[4]  E. Overton,et al.  Routine screening for depression: identifying a challenge for successful HIV care. , 2009, AIDS patient care and STDs.

[5]  J. Walkup,et al.  HIV patients with psychiatric disorders are less likely to discontinue HAART , 2009, AIDS (London).

[6]  Mardge H. Cohen,et al.  Trends in Mortality and Causes of Death Among Women With HIV in the United States: A 10-Year Study , 2009, Journal of acquired immune deficiency syndromes.

[7]  F. Altice,et al.  Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy , 2009, AIDS care.

[8]  N. Benbow,et al.  Demographic characteristics and survival with AIDS: health disparities in Chicago, 1993-2001. , 2009, American journal of public health.

[9]  B. Pence.  The impact of mental health and traumatic life experiences on antiretroviral treatment outcomes for people living with HIV/AIDS. , 2009, The Journal of antimicrobial chemotherapy.

[10]  Joshua D. Hartzell,et al.  Impact of depression on HIV outcomes in the HAART era. , 2008, The Journal of antimicrobial chemotherapy.

[11]  J. Leserman.  Role of depression, stress, and trauma in HIV disease progression. , 2008, Psychosomatic medicine.

[12]  D. Cheng,et al.  Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems , 2008, AIDS.

[13]  J. Fleishman,et al.  Access to HAART and utilization of inpatient medical hospital services among HIV-infected patients with co-occurring serious mental illness and injection drug use. , 2007, General hospital psychiatry.

[14]  T. Patterson,et al.  The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART , 2007, AIDS.

[15]  W. Fawzi,et al.  Depressive Symptoms Increase Risk of HIV Disease Progression and Mortality Among Women in Tanzania , 2007, Journal of acquired immune deficiency syndromes.

[16]  C. Weisner,et al.  The Excess Medical Cost And Health Problems of Family Members of Persons Diagnosed With Alcohol or Drug Problems , 2007, Medical care.

[17]  Mardge H. Cohen,et al.  Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  J. Miranda,et al.  Disparities in care for depression among primary care patients , 2004, Journal of General Internal Medicine.

[19]  M. G. Fonseca,et al.  AIDS mortality, "race or color", and social inequality in a context of universal access to highly active antiretroviral therapy (HAART) in Brazil, 1999-2004. , 2007, Cadernos de saude publica.

[20]  Melissa R Pfeiffer,et al.  Causes of Death among Persons with AIDS in the Era of Highly Active Antiretroviral Therapy: New York City , 2006, Annals of Internal Medicine.

[21]  W. Miller,et al.  Prevalence of DSM-IV-Defined Mood, Anxiety, and Substance Use Disorders in an HIV Clinic in the Southeastern United States , 2006, Journal of acquired immune deficiency syndromes.

[22]  D. Satre,et al.  Chemical dependency patients with cooccurring psychiatric diagnoses: service patterns and 1-year outcomes. , 2006, Alcoholism, clinical and experimental research.

[23]  Robert C. Saunders,et al.  Racial and gender differences in utilization of Medicaid substance abuse services among adolescents. , 2006, Psychiatric services.

[24]  Richard D Moore,et al.  Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. , 2006, American journal of epidemiology.

[25]  D. Nash,et al.  Trends in predictors of death due to HIV-related causes among persons living with AIDS in New York City: 1993–2001 , 2005, Journal of Urban Health.

[26]  C. Fairley,et al.  Long‐term utility of measuring adherence by self‐report compared with pharmacy record in a routine clinic setting , 2005, HIV medicine.

[27]  C. Weisner,et al.  Hazardous drinkers and drug users in HMO primary care: prevalence, medical conditions, and costs. , 2005, Alcoholism, clinical and experimental research.

[28]  N. Horton,et al.  Substance abuse treatment and hospitalization among a cohort of HIV-infected individuals with alcohol problems. , 2005, Alcoholism, clinical and experimental research.

[29]  Richard D Moore,et al.  Does the Presence of a Current Psychiatric Disorder in AIDS Patients Affect the Initiation of Antiretroviral Treatment and Duration of Therapy? , 2004, Journal of acquired immune deficiency syndromes.

[30]  Susan M. Richey,et al.  The Veterans Aging Cohort Study: observational studies of alcohol use, abuse, and outcomes among human immunodeficiency virus-infected veterans. , 2004, Alcoholism, clinical and experimental research.

[31]  C. Weisner,et al.  Medical and psychiatric conditions of alcohol and drug treatment patients in an HMO: comparison with matched controls. , 2003, Archives of internal medicine.

[32]  P. Joyce,et al.  The effect of a history of alcohol dependence in adult major depression. , 2002, Journal of affective disorders.

[33]  Richard D Moore,et al.  Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic , 2002, AIDS.

[34]  C. Weisner,et al.  Integrating primary medical care with addiction treatment: a randomized controlled trial. , 2001, JAMA.

[35]  C. Sherbourne,et al.  Use of mental health and substance abuse treatment services among adults with HIV in the United States. , 2001, Archives of general psychiatry.

[36]  L. Kalish,et al.  Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease , 2001, Annals of Internal Medicine.

[37]  D. Vlahov,et al.  Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. , 2001, JAMA.

[38]  R. Hogg,et al.  Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[39]  D. Perkins,et al.  Progression to AIDS: the effects of stress, depressive symptoms, and social support. , 1999, Psychosomatic medicine.

[40]  A Muñoz,et al.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.

[41]  N. Krieger.  Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. , 1992, American journal of public health.